BLyS antagonists and peptide tolerance induction

Lupus

Volumn 14, Issue 3, 2005, Pages 204-209

  Merrill, Joan T ^a  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Biologic treatments; Drug development; Systemic lupus

Indexed keywords

APRIL PROTEIN; AUTOANTIBODY; BAFF R PROTEIN; BCMA PROTEIN; BELIMUMAB; BLYS PROTEIN; CELL SURFACE PROTEIN; EDRATIDE; GAMMA INTERFERON; INTERLEUKIN 10; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3E10; PROTEIN BCL 2; TACI PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIGEN RECOGNITION; AUTOIMMUNITY; CLONAL ANERGY; COMPLEMENTARITY DETERMINING REGION; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; GENETIC POLYMORPHISM; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; MONKEY; MONONUCLEAR CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; B-CELL ACTIVATING FACTOR; HUMANS; IMMUNE TOLERANCE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEMBRANE PROTEINS; PEPTIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15944396964     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1191/0961203303lu2137oa     Document Type: Conference Paper

References (53)

1. Kammer GM, Laxminarayana D, Khan IU. Mechanisms of deficient Type I protein kinase A activity in lupus T lymphocytes. Int Rev Immunol 2004; 23: 225-244.
2. Takeuchi T, Tsuzaka K, Abe T. Altereed expression of the Tcell receptor-CD3 complex in SLE. Int Rev Immunol 2004; 23: 273-291.
3. Grammer AC, Lipsky PE. B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 2003 5(Suppl. 4): S22-27.
4. Arbuckle MR, Reichlin M, Harley JB, James JA. Shared early autoantibody recognition events in the development of anti-Sm B/B in human lupus. Scand J Immunol 1999; 50: 447-455.
5. James JA, Harley JB. A model of peptide-induced lupus autoimmune B cell epitope spreading is strain specific and is not H-2 restricted in mice. J Immunol 1998; 160: 502-508.
6. Jego G, Pascual V, Palucka AK, Banchereau J. Dendritic cells control B cell growth and differentiation. Curr Dir Autoimmun 2005; 8: 124-139.
7. Hase H, Kanno Y, Kojima M et al. BAFF/BLyS can potentiate B-cell selection with the B-cell coreceptor complex. Blood 2004; 103: 2257-2265.
8. Nardelli B, Belvedere O, Roschke V et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 2001; 97: 198-204.
9. Tardivel A, Tinel A, Lens S et al. The anti-apoptotic factor Bcl-2 can functionally substitute for the B cell survival but not for the marginal zone B cell differentiation activity of BAFF. Eur J Immunol 2004; 34: 509-518.
10. Zhang J, Roschke V, Baker KP et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001; 166: 6-10.
11. Moore PA, Belvedere O, Orr A et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999; 285: 260-263.
12. Litinskiy MB, Nardelli B, Hubert DM et al. DCs induce CD40-independent immunoglobulin class switching through BLyS and APRIL. Nat Immunol 2002; 3: 822-829.
13. Gross JA, Dillon SR, Mudri S et al. TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BlyS. Immunity 2001; 15: 289-302.
14. Yu G, Boone T, Delaney J et al. APRIL and TALL-I and receptors BCMA and TACI: system for regulating humoral immunity. Nat Immunol 2000; 1: 252-256.
15. Cancro MP. The BLyS family of ligands and receptors: an archetype for niche-specific homeostatic regulation. Immunol Rev 2004; 202: 237-249.
16. Wu Y, Bressette D, Carrell JA et al. Tumor necrosis factor (TNF) receptor superfamily member TACI is a high affinity receptor for TNF family members APRIL and BlyS. J Biol Chem 2000; 275: 35478-35485.
17. Marsters SA, Yan M, Pitti RM, Haas PE, Dixit VM, Ashkenazi A. Interaction of the TNF homologues BLyS and APRIL with the TNF receptor homologues BCMA and TACI. Curr Biol 2000; 10: 785-788.
18. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 2004; 173: 2245-2252.
19. O'Connor BP, Raman VS, Erickson LD et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004; 199: 91-98.
20. Varfolomeev E, Kischkel F, Martin F et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004; 24: 997-1006.
21. Roschke V, Sosnovtseva S, Ward CD et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002; 169: 4314-4321.
22. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003; 18: 279-288.
23. Rahman ZS, Rao SP, Kalled SL, Manser T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003; 198: 1157-1169.
24. Stohl W, Metyas S, Tan SM et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004; 63: 1096-1103.
25. Stohl W. A therapeutic role for BLyS antagonists. Lupus 2004; 13: 317-322.
26. Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003; 48: 3475-3486.
27. Stohl W. SLE-systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther 2003; 5: 136-138.
28. Kawasaki A, Tsuchiya N, Fukazawa T, Hashimoto H, Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002; 3: 424-429.
29. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001; 44: 1313-1319.
30. Merrill JT, Erkan D, Buyon JP. Challenges in bringing the bench to bedside in drug development for SLE. Nat Rev Drug Discov 2004; 3: 1036-1046.
31. Baker KP, Edwards BM, Main SH et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003; 483: 253-265.
32. Rahman A. Autoantibodies, lupus and the science of sabotage. Rheumatology (Oxford) 2004; 43: 1326-1336.
33. Schluter SF, Adelman MK, Taneja V, David C, Yocum DE, Marchalonis JJ. Natural autoantibodies to TCR public idiotopes: potential roles in immunomodulation. Cell Mol Biol 2003; 49: 193-207.
34. Schluter SF, Wang E, Winfield JB, Yocum DE, Marchalonis JJ. Autoregulation of Tcr V region epitopes in autoimmune disease. Adv Exp Med Biol 1995; 383: 231-236.
35. Schluter SF, Adelman MK, Taneja V, David C, Yocum DE, Marchalonis JJ. Natural autoantibodies to TCR public idiotopes: potential roles in immunomodulation. Cell Mol Biol 2003; 49: 193-207.
36. Escher R, Vogel M, Escher G, Miescher S, Stadler BM, Berchtold P. Recombinant anti-idiotypic antibodies inhibit human natural anti-glycoprotein (GP)IIb/IIIa autoantibodies. J Autoimmun 2002; 18: 71-81.
37. Kim SJ, Gershov D, Ma X, Brot N, Elkon KB. PLA(2) activation during apoptosis promotes the exposure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med 2002; 196: 655-665.
38. Pan ZJ, Anderson CJ, Stafford HA. Anti-idiotypic antibodies prevent the serologic detection of antiribosomal P autoantibodies in healthy adults. J Clin Invest 1998; 102: 215-222.
39. Marchalonis JJ, Schluter SF, Wang E et al. Synthetic autoantigens of immunoglobulins and T-cell receptors: their recognition in aging, infection, and autoimmunity. Proc Soc Exp Biol Med 1994; 207: 129-147.
40. Marchalonis JJ, Kaymaz H, Schluter SF, Yocum DE. Human autoantibodies to a synthetic putative T cell receptor beta-chain regulatory idiotype: expression in autoimmunity and aging. Exp Clin Immunogenet 1993; 10: 1-15.
41. Kalsi JK, Grossman J, Kim J et al. Peptides from antibodies to DNA elicit cytokine release from peripheral blood mononuclear cells of patients with systemic lupus erythematosus: relation of cytokine pattern to disease duration. Lupus 2004; 13: 490-500.
42. Faber-Elmann A, Eilat E, Zinger H, Mozes E. A peptide based on an anti-DNA autoantibody downregulates matrix metalloproteinases in murine models of lupus. Clin Immunol 2002; 105: 223-232.
43. Eilat E, Dayan M, Zinger H, Mozes E. The mechanism by which a peptide based on complementarity-determining region-1 of a pathogenic anti-DNA auto-Ab ameliorates experimental systemic lupus erythematosus. Proc Natl Acad Sci USA 2001; 98: 1148-1153.
44. Eilat E, Zinger H, Nyska A, Mozes E. Prevention of systemic lupus erythematosus-like disease in (NZB × NZW)F1 mice by treating with CDR1- and CDR3-based peptides of a pathogenic autoantibody. J Clin Immunol 2000; 20: 268-278.
45. Eilat E, Fridkin M, Mozes E. A peptide based on the CDR1 of a pathogenic anti-DNA antibody is more efficient than its analogs in inhibiting autoreactive T cells. Immunobiology 2000; 202: 383-393.
46. Ehrenstein MR, Hahn B. T cell-B cell interactions. Lupus 2002; 11: 790-792.
47. Singh RR, Kumar V, Ebling FM et al. T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J Exp Med 1995; 181: 2017-2027.
48. Hahn BH, Singh RR, Ebling FM. Self Ig peptides that help anti-DNA antibody production: importance of charged residues. Lupus 1998; 7: 307-313.
49. Ebling FM, Tsao BP, Singh RR, Sercarz E, Hahn BH. A peptide derived from an autoantibody can stimulate T cells in the (NZB × NZW)F1 mouse model of systemic lupus erythematosus. Arthritis Rheum 1993; 36: 355-364.
50. Spertini F, Leimgruber A, Morel B et al. Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis. J Rheumatol 1999; 26: 2602-2608.
51. Teva website: http://www.tevapharm.com/research/products_np.asp.
52. Waisman A, Ruiz PJ, Israelie E et al. Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibody. Proc Nat Acad Sci 1997; 94: 4620-4625.
53. Dayab M, Segal R, Sthoeger Z et al. Immune response of SLE patients to peptides based on the complementary determining regions of a pathogenic anti-DNA monoclonal antibody. J Clin Immunol 2000; 20: 187-192.